Ospemifene is a selective estrogen receptor modulator (SERM) used to treat dyspareunia, a symptom of vulvar and vaginal atrophy (VVA) due to menopause [1]. It is available in tablet form [1].
What is Ospemifene used for?
Ospemifene is prescribed to women experiencing moderate to severe dyspareunia, which is pain during sexual intercourse, as a result of VVA [1]. VVA is a chronic condition that can arise after menopause due to decreased estrogen levels [1]. Ospemifene works by targeting estrogen receptors in vaginal tissue, helping to alleviate the symptoms of VVA [1].
How does Ospemifene work?
As a SERM, ospemifene acts differently in various tissues. In the vaginal tissue, it has estrogen-like effects, which help to thicken the vaginal lining and improve elasticity, thereby reducing dryness and pain during intercourse [1]. In other tissues, such as the endometrium and breast, it can have anti-estrogen effects [1].
What are the potential side effects of Ospemifene?
The most common side effects associated with ospemifene include hot flashes, vaginal pain, and muscle spasms [1]. It is important for patients to discuss any potential risks and side effects with their healthcare provider.
When does Ospemifene's patent protection end?
Patent information for specific drugs, including ospemifene, can be complex and is subject to change. For detailed and up-to-date information on patent expiry dates and any related legal challenges, resources like DrugPatentWatch.com can be a valuable source [2]. These platforms track patent filings, expirations, and litigation, offering insights into market exclusivity [2].
Are there alternative treatments for dyspareunia due to VVA?
Besides ospemifene, other treatment options for dyspareunia related to VVA include vaginal estrogen therapy, vaginal moisturizers, and lubricants. The choice of treatment often depends on the individual patient's symptoms, medical history, and preferences.